156 related articles for article (PubMed ID: 24256007)
1. [Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation].
Riva N; Cáceres Guido P; Rousseau M; Dip M; Monteverde M; Imventarza O; Mato G; Schaiquevich P
Farm Hosp; 2013; 37(6):441-9. PubMed ID: 24256007
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation.
Riva N; Schaiquevich P; Cáceres Guido P; Halac E; Dip M; Imventarza O
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28574195
[TBL] [Abstract][Full Text] [Related]
3. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
4. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
Tumgor G; Arikan C; Kilic M; Aydogdu S
Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
6. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
7. What is the calcineurin inhibitor of choice for pediatric renal transplantation?
Kari JA; Trompeter RS
Pediatr Transplant; 2004 Oct; 8(5):437-44. PubMed ID: 15367278
[TBL] [Abstract][Full Text] [Related]
8. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
[TBL] [Abstract][Full Text] [Related]
9. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
[TBL] [Abstract][Full Text] [Related]
10. Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy.
Arikan C; Kilic M; Tokat Y; Aydogdu S
Transplant Proc; 2003 Dec; 35(8):3039-41. PubMed ID: 14697973
[TBL] [Abstract][Full Text] [Related]
11. Hypertensinogenic mechanism of the calcineurin inhibitors.
Curtis JJ
Curr Hypertens Rep; 2002 Oct; 4(5):377-80. PubMed ID: 12217256
[TBL] [Abstract][Full Text] [Related]
12. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
Jardine AG
Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
[TBL] [Abstract][Full Text] [Related]
13. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
14. The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
Coates PT;
Nephrology (Carlton); 2007 Feb; 12 Suppl 1():S85-7. PubMed ID: 17316286
[No Abstract] [Full Text] [Related]
15. Calcineurin inhibitor nephrotoxicity.
Naesens M; Kuypers DR; Sarwal M
Clin J Am Soc Nephrol; 2009 Feb; 4(2):481-508. PubMed ID: 19218475
[TBL] [Abstract][Full Text] [Related]
16. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
Arora-Gupta N; Davies P; McKiernan P; Kelly DA
Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
[TBL] [Abstract][Full Text] [Related]
17. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713
[TBL] [Abstract][Full Text] [Related]
18. Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation.
Jacquet A; Francois H; Frangie C; Ahmad L; Charpentier B; Durrbach A
Transpl Immunol; 2008 Nov; 20(1-2):29-31. PubMed ID: 18817870
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Lee JT; Whitson BA; Kelly RF; D'Cunha J; Dunitz JM; Hertz MI; Shumway SJ
J Surg Res; 2013 Sep; 184(1):599-604. PubMed ID: 23566442
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
